Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Spatial Distance Correlates With Genetic Distance in Diffuse Glioma.

Gates EDH, Yang J, Fukumura K, Lin JS, Weinberg JS, Prabhu SS, Long L, Fuentes D, Sulman EP, Huse JT, Schellingerhout D.

Front Oncol. 2019 Jul 30;9:676. doi: 10.3389/fonc.2019.00676. eCollection 2019.

2.

Molecular Profiling of Long-Term IDH-wildtype Glioblastoma Survivors.

Burgenske DM, Yang J, Decker PA, Kollmeyer TM, Kosel ML, Mladek AC, Caron AA, Vaubel RA, Gupta SK, Kitange GJ, Sicotte H, Youland RS, Remonde D, Voss JS, Fritcher EGB, Kolsky KL, Ida CM, Meyer FB, Lachance DH, Parney IJ, Kipp BR, Giannini C, Sulman EP, Jenkins RB, Eckel-Passow JE, Sarkaria JN.

Neuro Oncol. 2019 Jul 26. pii: noz129. doi: 10.1093/neuonc/noz129. [Epub ahead of print]

PMID:
31346613
3.

Assembling the brain trust: the multidisciplinary imperative in neuro-oncology.

Ludmir EB, Mahajan A, Ahern V, Ajithkumar T, Alapetite C, Bernier-Chastagner V, Bindra RS, Bishop AJ, Bolle S, Brown PD, Carrie C, Chalmers AJ, Chang EL, Chung C, Dieckmann K, Esiashvili N, Gandola L, Ghia AJ, Gondi V, Grosshans DR, Harrabi SB, Horan G, Indelicato DJ, Jalali R, Janssens GO, Krause M, Laack NN, Laperriere N, Laprie A, Li J, Marcus KJ, McGovern SL, Merchant TE, Merrell KW, Padovani L, Parkes J, Paulino AC, Schwarz R, Shih HA, Souhami L, Sulman EP, Taylor RE, Thorp N, Timmermann B, Wheeler G, Wolden SL, Woodhouse KD, Yeboa DN, Yock TI, Kortmann RD, McAleer MF.

Nat Rev Clin Oncol. 2019 Aug;16(8):521-522. doi: 10.1038/s41571-019-0235-z. No abstract available.

PMID:
31150024
4.

Identification of patient-derived glioblastoma stem cell (GSC) lines with the alternative lengthening of telomeres phenotype.

Farooqi A, Yang J, Sharin V, Ezhilarasan R, Danussi C, Alvarez C, Dharmaiah S, Irvin D, Huse J, Sulman EP.

Acta Neuropathol Commun. 2019 May 16;7(1):76. doi: 10.1186/s40478-019-0732-4. No abstract available.

5.

Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair.

Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB.

Cancer Cell. 2019 May 13;35(5):816. doi: 10.1016/j.ccell.2019.04.011. No abstract available.

PMID:
31085179
6.

Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair.

Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB.

Cancer Cell. 2019 Mar 18;35(3):504-518.e7. doi: 10.1016/j.ccell.2019.01.020. Epub 2019 Feb 28. Erratum in: Cancer Cell. 2019 May 13;35(5):816.

PMID:
30827889
7.

G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.

Wang Y, Yang J, Wild AT, Wu WH, Shah R, Danussi C, Riggins GJ, Kannan K, Sulman EP, Chan TA, Huse JT.

Nat Commun. 2019 Feb 26;10(1):943. doi: 10.1038/s41467-019-08905-8.

8.

Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation.

Minata M, Audia A, Shi J, Lu S, Bernstock J, Pavlyukov MS, Das A, Kim SH, Shin YJ, Lee Y, Koo H, Snigdha K, Waghmare I, Guo X, Mohyeldin A, Gallego-Perez D, Wang J, Chen D, Cheng P, Mukheef F, Contreras M, Reyes JF, Vaillant B, Sulman EP, Cheng SY, Markert JM, Tannous BA, Lu X, Kango-Singh M, Lee LJ, Nam DH, Nakano I, Bhat KP.

Cell Rep. 2019 Feb 12;26(7):1893-1905.e7. doi: 10.1016/j.celrep.2019.01.076.

9.

High-Throughput Automated Single-Cell Imaging Analysis Reveals Dynamics of Glioblastoma Stem Cell Population During State Transition.

Chumakova AP, Hitomi M, Sulman EP, Lathia JD.

Cytometry A. 2019 Mar;95(3):290-301. doi: 10.1002/cyto.a.23728. Epub 2019 Feb 6.

PMID:
30729665
10.

A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma.

Milgrom SA, Elhalawani H, Lee J, Wang Q, Mohamed ASR, Dabaja BS, Pinnix CC, Gunther JR, Court L, Rao A, Fuller CD, Akhtari M, Aristophanous M, Mawlawi O, Chuang HH, Sulman EP, Lee HJ, Hagemeister FB, Oki Y, Fanale M, Smith GL.

Sci Rep. 2019 Feb 4;9(1):1322. doi: 10.1038/s41598-018-37197-z.

11.

MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.

Huang T, Wan X, Alvarez AA, James CD, Song X, Yang Y, Sastry N, Nakano I, Sulman EP, Hu B, Cheng SY.

Autophagy. 2019 Jun;15(6):1100-1111. doi: 10.1080/15548627.2019.1569947. Epub 2019 Jan 31.

PMID:
30654687
12.

ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features.

Olar A, Tran D, Mehta VP, Reinhardt A, Manekia JH, Garnovskaya M, Ellezam B, Luthra R, Sulman EP, Mohila CA, Campbell GA, Powell SZ, Fuller GN, Aldape KD, Adesina AM.

Clin Neuropathol. 2019 Mar/Apr;38(2):59-73. doi: 10.5414/NP301105.

PMID:
30499772
13.

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.

Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides TP, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS.

Clin Cancer Res. 2019 Feb 15;25(4):1261-1271. doi: 10.1158/1078-0432.CCR-18-2312. Epub 2018 Nov 5.

PMID:
30397180
14.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2019 Feb 1;125(3):424-433. doi: 10.1002/cncr.31811. Epub 2018 Oct 25. Erratum in: Cancer. 2019 Apr 15;125(8):1387.

PMID:
30359477
15.

BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor.

Jour G, Vasudevaraja V, Prieto VG, Snuderl M, Torres-Cabala CA, Al-Rohil R, Sulman EP, Ballester LY, Aung PP.

Mod Pathol. 2019 Mar;32(3):338-345. doi: 10.1038/s41379-018-0146-z. Epub 2018 Oct 11.

PMID:
30310175
16.

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.

Yuan AL, Ricks CB, Bohm AK, Lun X, Maxwell L, Safdar S, Bukhari S, Gerber A, Sayeed W, Bering EA, Pedersen H, Chan JA, Shen Y, Marra M, Kaplan DR, Mason W, Goodman LD, Ezhilarasan R, Kaufmann AB, Cabral M, Robbins SM, Senger DL, Cahill DP, Sulman EP, Cairncross JG, Blough MD.

PLoS One. 2018 Aug 28;13(8):e0202860. doi: 10.1371/journal.pone.0202860. eCollection 2018.

17.

A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models.

Zinn PO, Singh SK, Kotrotsou A, Hassan I, Thomas G, Luedi MM, Elakkad A, Elshafeey N, Idris T, Mosley J, Gumin J, Fuller GN, de Groot JF, Baladandayuthapani V, Sulman EP, Kumar AJ, Sawaya R, Lang FF, Piwnica-Worms D, Colen RR.

Clin Cancer Res. 2018 Dec 15;24(24):6288-6299. doi: 10.1158/1078-0432.CCR-17-3420. Epub 2018 Jul 27.

PMID:
30054278
18.

The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.

Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G.

J Natl Cancer Inst. 2019 Mar 1;111(3):292-300. doi: 10.1093/jnci/djy107.

19.

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA.

J Clin Oncol. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. Epub 2018 Jun 15.

20.

A gene expression signature predicts recurrence-free survival in meningioma.

Olar A, Goodman LD, Wani KM, Boehling NS, Sharma DS, Mody RR, Gumin J, Claus EB, Lang FF, Cloughesy TF, Lai A, Aldape KD, DeMonte F, Sulman EP.

Oncotarget. 2018 Feb 15;9(22):16087-16098. doi: 10.18632/oncotarget.24498. eCollection 2018 Mar 23.

21.

Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.

Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB.

Oncoimmunology. 2018 Jan 16;7(4):e1412909. doi: 10.1080/2162402X.2017.1412909. eCollection 2018.

22.

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.

Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT.

Nat Commun. 2018 Mar 13;9(1):1057. doi: 10.1038/s41467-018-03476-6.

23.

Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.

Luedi MM, Singh SK, Mosley JC, Hassan ISA, Hatami M, Gumin J, Andereggen L, Sulman EP, Lang FF, Stueber F, Fuller GN, Colen RR, Zinn PO.

J Neurosurg. 2018 Dec 1;129(6):1446-1455. doi: 10.3171/2017.7.JNS17668.

PMID:
29328002
24.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauvé CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2018 Jan 8;33(1):152. doi: 10.1016/j.ccell.2017.12.012. No abstract available.

25.

Large Scale Identification of Variant Proteins in Glioma Stem Cells.

Mostovenko E, Végvári Á, Rezeli M, Lichti CF, Fenyö D, Wang Q, Lang FF, Sulman EP, Sahlin KB, Marko-Varga G, Nilsson CL.

ACS Chem Neurosci. 2018 Jan 17;9(1):73-79. doi: 10.1021/acschemneuro.7b00362. Epub 2017 Dec 21.

26.

MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma.

Huang T, Kim CK, Alvarez AA, Pangeni RP, Wan X, Song X, Shi T, Yang Y, Sastry N, Horbinski CM, Lu S, Stupp R, Kessler JA, Nishikawa R, Nakano I, Sulman EP, Lu X, James CD, Yin XM, Hu B, Cheng SY.

Cancer Cell. 2017 Dec 11;32(6):840-855.e8. doi: 10.1016/j.ccell.2017.11.005.

27.

Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy.

Fang P, Boehling NS, Koay EJ, Bucheit AD, Jakob JA, Settle SH, Brown PD, Davies MA, Sulman EP.

J Neurooncol. 2018 Mar;137(1):67-75. doi: 10.1007/s11060-017-2695-2. Epub 2017 Dec 2.

PMID:
29198052
28.

GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma.

Moreno M, Pedrosa L, Paré L, Pineda E, Bejarano L, Martínez J, Balasubramaniyan V, Ezhilarasan R, Kallarackal N, Kim SH, Wang J, Audia A, Conroy S, Marin M, Ribalta T, Pujol T, Herreros A, Tortosa A, Mira H, Alonso MM, Gómez-Manzano C, Graus F, Sulman EP, Piao X, Nakano I, Prat A, Bhat KP, de la Iglesia N.

Cell Rep. 2017 Nov 21;21(8):2183-2197. doi: 10.1016/j.celrep.2017.10.083.

29.

A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma.

Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP.

Oncotarget. 2017 Oct 12;8(52):90488-90495. doi: 10.18632/oncotarget.21799. eCollection 2017 Oct 27.

30.

PAF promotes stemness and radioresistance of glioma stem cells.

Ong DST, Hu B, Ho YW, Sauvé CG, Bristow CA, Wang Q, Multani AS, Chen P, Nezi L, Jiang S, Gorman CE, Monasterio MM, Koul D, Marchesini M, Colla S, Jin EJ, Sulman EP, Spring DJ, Yung WA, Verhaak RGW, Chin L, Wang YA, DePinho RA.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9086-E9095. doi: 10.1073/pnas.1708122114. Epub 2017 Oct 9.

31.

Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.

Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, Neal BP, Boroda S, Li M, Brenneman B, Abounader R, Floyd D, Lee J, Nakano I, Godlewski J, Bronisz A, Sulman EP, Mayo M, Gioeli D, Weber M, Harris TE, Purow B.

Neuro Oncol. 2018 Jan 22;20(2):192-202. doi: 10.1093/neuonc/nox119.

32.

Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.

An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J.

Radiother Oncol. 2017 Oct;125(1):80-88. doi: 10.1016/j.radonc.2017.08.009. Epub 2017 Sep 12.

PMID:
28916225
33.

CDK4/6 inhibition is more active against the glioblastoma proneural subtype.

Li M, Xiao A, Floyd D, Olmez I, Lee J, Godlewski J, Bronisz A, Bhat KPL, Sulman EP, Nakano I, Purow B.

Oncotarget. 2017 Jul 21;8(33):55319-55331. doi: 10.18632/oncotarget.19429. eCollection 2017 Aug 15.

34.

APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death.

Wang Y, Wu S, Zheng S, Wang S, Wali A, Ezhilarasan R, Sulman EP, Koul D, Alfred Yung WK.

Oncotarget. 2017 Apr 21;8(33):54285-54296. doi: 10.18632/oncotarget.17348. eCollection 2017 Aug 15.

35.

Glioblastoma stem cells exploit the αvβ8 integrin-TGFβ1 signaling axis to drive tumor initiation and progression.

Guerrero PA, Tchaicha JH, Chen Z, Morales JE, McCarty N, Wang Q, Sulman EP, Fuller G, Lang FF, Rao G, McCarty JH.

Oncogene. 2017 Nov 23;36(47):6568-6580. doi: 10.1038/onc.2017.248. Epub 2017 Aug 7.

36.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):152.

37.

Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.

Canella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu J, Gumin J, Lang FF, Gurcan MN, Kaur B, Sampath D, Puduvalli VK.

Clin Cancer Res. 2017 Oct 15;23(20):6215-6226. doi: 10.1158/1078-0432.CCR-16-3151. Epub 2017 Jul 5.

38.

MerTK as a therapeutic target in glioblastoma.

Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR.

Neuro Oncol. 2018 Jan 10;20(1):92-102. doi: 10.1093/neuonc/nox111.

39.

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.

Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.

Neuro Oncol. 2017 May 1;19(5):669-677. doi: 10.1093/neuonc/now208.

40.

Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.

Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, Fuller GN, Goodman L, Sulman EP, Lang FF.

Neuro Oncol. 2017 May 1;19(5):660-668. doi: 10.1093/neuonc/now239.

41.

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.

Koul D, Wang S, Wu S, Saito N, Zheng S, Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, Shiose Y, Sulman EP, Hirota Y, Yung WKA.

Oncotarget. 2017 Mar 28;8(13):21741-21753. doi: 10.18632/oncotarget.15566.

42.

Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.

Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routbort MJ.

J Neuropathol Exp Neurol. 2017 Mar 1;76(3):179-188. doi: 10.1093/jnen/nlw119.

PMID:
28395087
43.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

44.

Ionizing radiation augments glioma tropism of mesenchymal stem cells.

Thomas JG, Parker Kerrigan BC, Hossain A, Gumin J, Shinojima N, Nwajei F, Ezhilarasan R, Love P, Sulman EP, Lang FF.

J Neurosurg. 2018 Jan;128(1):287-295. doi: 10.3171/2016.9.JNS16278. Epub 2017 Mar 31.

45.

m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program.

Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, Chen Y, Sulman EP, Xie K, Bögler O, Majumder S, He C, Huang S.

Cancer Cell. 2017 Apr 10;31(4):591-606.e6. doi: 10.1016/j.ccell.2017.02.013. Epub 2017 Mar 23.

46.

Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.

Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DT, Pfister SM, Sulman EP, Aldape KD.

Acta Neuropathol. 2017 Mar;133(3):431-444. doi: 10.1007/s00401-017-1678-x. Epub 2017 Jan 27.

47.

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK.

Neuro Oncol. 2017 Jul 1;19(7):965-975. doi: 10.1093/neuonc/now257.

48.

Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.

Sulman EP, Ismaila N, Chang SM.

J Oncol Pract. 2017 Feb;13(2):123-127. doi: 10.1200/JOP.2016.018937. Epub 2016 Nov 29. No abstract available.

PMID:
27907278
49.

Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.

Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM.

J Clin Oncol. 2017 Jan 20;35(3):361-369. doi: 10.1200/JCO.2016.70.7562. Epub 2016 Nov 28. Review.

PMID:
27893327
50.

Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth.

Hu B, Wang Q, Wang YA, Hua S, Sauvé CG, Ong D, Lan ZD, Chang Q, Ho YW, Monasterio MM, Lu X, Zhong Y, Zhang J, Deng P, Tan Z, Wang G, Liao WT, Corley LJ, Yan H, Zhang J, You Y, Liu N, Cai L, Finocchiaro G, Phillips JJ, Berger MS, Spring DJ, Hu J, Sulman EP, Fuller GN, Chin L, Verhaak RGW, DePinho RA.

Cell. 2016 Nov 17;167(5):1281-1295.e18. doi: 10.1016/j.cell.2016.10.039.

Supplemental Content

Loading ...
Support Center